LivaNova PLC, a global medical technology company headquartered in London, has announced the appointment of Jette Nygaard-Andersen to its Board of Directors. The appointment, effective immediately, sees Nygaard-Andersen bringing a wealth of experience from her distinguished career, including her recent tenure as CEO of FTSE 100 gambling giant Entain.
Nygaard-Andersen's career spans over two decades, during which she has held various leadership positions focusing on digital transformation, strategy, and operations across multiple sectors. Her experience at Entain, where she oversaw a significant period of growth and strategic change, is particularly relevant. Prior to Entain, she held senior roles at Modern Times Group (MTG), a leading international entertainment group, where she was instrumental in driving digital initiatives and business development.
At LivaNova, Nygaard-Andersen will serve on both the Nomination & Governance Committee and the Audit Committee. Her expertise in corporate governance and strategic oversight is expected to be a valuable asset as LivaNova continues to innovate and expand its presence in the medical technology sector. The company specialises in developing and delivering therapeutic solutions for cardiovascular and neuromodulation diseases, with products such as vagus nerve stimulation (VNS) for epilepsy and depression, and advanced cardiovascular products.
This strategic board appointment comes at a time when medical technology companies are increasingly focusing on digital health solutions and navigating complex regulatory landscapes. Nygaard-Andersen's background in leading large, publicly traded companies through periods of technological change and market evolution aligns well with LivaNova's ongoing objectives to enhance patient outcomes through innovative therapies.
The addition of a director with such a strong track record in operational leadership and corporate strategy is often viewed positively by investors and analysts, as it signals a commitment to robust governance and forward-thinking leadership. LivaNova, listed on the NASDAQ stock exchange, operates in a highly competitive global market, and strengthening its board is a key component of its long-term growth strategy.
LivaNova's commitment to advancing medical science and improving patient lives through its neurostimulation and cardiovascular portfolios underscores the importance of having a diverse and experienced board to guide its trajectory. Nygaard-Andersen's appointment is a clear indication of the company's intent to draw on top-tier talent to achieve its strategic ambitions.
Source: LivaNova PLC